Abbott Laboratories (ABT) Total Non-Current Liabilities (2009 - 2021)

Abbott Laboratories has disclosed Total Non-Current Liabilities across 13 years of filings, most recently posting -$20.9 billion for Q4 2021.

• Total Non-Current Liabilities for Q4 2021 came in at -$20.9 billion, up 16.23% year-over-year; the trailing twelve-month figure through Dec 2021 was -$20.9 billion (up 16.23% YoY), and the FY2021 annual result was -$20.9 billion, up 16.23% from the prior year.
• Total Non-Current Liabilities came in at -$20.9 billion for Q4 2021 at Abbott Laboratories, up from -$24.9 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $48.2 billion in Q4 2017 to a low of -$24.9 billion in Q4 2020.
• The 5-year median for Total Non-Current Liabilities is $1.3 billion (2019), against an average of $8.5 billion.
• Across the five-year window, Total Non-Current Liabilities surged 113.68% in 2017 and sank 2024.46% in 2020, its largest moves.
• Abbott Laboratories' Total Non-Current Liabilities stood at $48.2 billion in 2017, then retreated by 19.84% to $38.6 billion in 2018, then tumbled by 96.65% to $1.3 billion in 2019, then tumbled by 2024.46% to -$24.9 billion in 2020, then advanced by 16.23% to -$20.9 billion in 2021.
• The last three Total Non-Current Liabilities figures came in at -$20.9 billion (Q4 2021), -$24.9 billion (Q4 2020), and $1.3 billion (Q4 2019), per Business Quant data.